Research analysts covering Semnur Pharmaceuticals.
Recent press releases and 8-K filings for SMNR.
Semnur Pharmaceuticals, Inc. Updates Securities Description Post-Business Combination
SMNR
M&A
Delisting/Listing Issues
- Semnur Pharmaceuticals, Inc. consummated a business combination on September 22, 2025. As of December 3, 2025, the company has 229,740,978 shares of Common Stock and 5,423,606 shares of Series A Preferred Stock issued and outstanding.
- The 5,423,606 shares of Series A Preferred Stock were issued to Scilex Holding Company. These shares are not convertible into Common Stock or redeemable by Semnur , rank senior to Common Stock in liquidation, and have a liquidation preference of $10.00 per share (plus accrued dividends) or the as-converted value, whichever is greater.
- Public Warrants entitle holders to purchase one share of Common Stock at an exercise price of $11.50 per share and will expire five years from the consummation of the Business Combination. Semnur may redeem the warrants at $0.01 if the Common Stock's sales price equals or exceeds $16.50 for 20 trading days within a 30-day period.
- Shares of Common Stock and Public Warrants are quoted on the Pink Limited Market of the OTC Markets Group, Inc. under the symbols "SMNR" and "SMNRW", respectively.
Dec 3, 2025, 9:20 PM
Semnur Pharmaceuticals Completes Business Combination and Secures Bitcoin Investment
SMNR
M&A
New Projects/Investments
Delisting/Listing Issues
- Semnur Pharmaceuticals, Inc. completed its business combination with Denali Capital Acquisition Corp. on September 22, 2025, and its shares and warrants began trading on the OTC Markets on September 23, 2025, under ticker symbols SMNR and SMNRW, respectively.
- Scilex Holding Company, Semnur's majority owner, holds approximately 87.5% of Semnur common stock post-business combination.
- On September 23, 2025, Semnur entered into a Securities Purchase Agreement to sell $100 million of common stock to an institutional investor in exchange for $100 million in Bitcoin, with the investor receiving 6,250,000 shares at $16.00 per share.
- For the six months ended June 30, 2025, Semnur reported a net loss of $1.7 million and had cash and cash equivalents of $55,000, with an accumulated deficit of $117.0 million.
- Management has concluded that there is substantial doubt about the Company's ability to continue as a going concern for one year after the financial statements were issued.
Sep 26, 2025, 8:06 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more